PK and Metabolism

Quotient Bioresearch is a leader in using ¹⁴C-labelled drug products to evaluate PK and profile metabolites. Our pioneering use of these techniques has enabled the evaluation of drug performance in the clinic earlier and faster than ever before.  Future applications will undoubtedly develop to include tissue sampling and biomarker assessments where ultra-sensitive detection is vital. 

Our unique Synthesis-to-Clinic™ platform allows ¹⁴C clinical studies to be delivered as a fully integrated service from initial synthesis of ¹⁴C labelled API right through to reporting of clinical studies.

Quotient Bioresearch is recognised as the expert in conducting:

• “Phase 0” Microdose/Candidate Selection studies
• ivMicrotracer™ studies
• Human mass balance and metabolite profiling